Germ-Line Mutations in Blood and Saliva Samples From Patients With Cancer

PRIMARY OBJECTIVES:

I. To collect germ-line deoxyribonucleic acid (DNA) and nucleic acids from cancer patients to
further investigate the association and identify new germ-line mutations that impact cancer
predisposition.

II. To investigate the role of germ-line mutations in predicting cancer outcome and response
to therapy.

SECONDARY OBJECTIVES:

I. To determine the effect of the identified variants on tumor micro-ribonucleic acid
(miRNA), protein and gene expression.

II. To study expression of DNA, ribonucleic acid (RNA) or protein in the blood of cancer
patients with and without variants of interest to discover correlations between such levels
and the presence of cancer and/or response to therapy in these patients.

OUTLINE:

Patients undergo collection of blood and saliva samples 1-3 times at the discretion of the
investigator for germ-line mutation analysis.

After completion of study, patients are followed up for 5 years.

Inclusion Criteria:

- Pathologically or clinical confirmed tissue diagnosis of a cancer

- Ability to understand and the willingness to sign a written informed consent

Exclusion Criteria:

- Patients will be excluded if their cancer cannot be confirmed

- Refusal to sign the informed consent